Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Galderma

Status and phase: Completed; Phase 3

Conditions: Glabellar Frown Lines

Treatments: Biological: AbobotulinumtoxinA; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT03960957

43USD1805

Details and patient eligibility

About

An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines

Enrollment: 301 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Moderate to severe glabellar lines at maximum frown
• Understands the study requirements and signs an informed consent form

Exclusion criteria

• Botulinum toxin treatment in the face within 6 months prior to study treatment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

301 participants in 2 patient groups, including a placebo group

Experimental

Experimental group

Description:

AbobotulinumtoxinA

Treatment:

Biological: AbobotulinumtoxinA

Placebo

Placebo Comparator group

Treatment:

Other: Placebo